



Notice Regarding Availability of 340B Pricing for Sole Community Hospitals, Rural Referral Centers, Critical Access Hospitals, and Free Standing Cancer Hospitals for the Former Genentech Product Klonopin for the time period April 1, 2011 through December 31, 2021.

Genentech has recently discovered that there is a discrepancy regarding the Orphan Drug Designation status of Klonopin (clonazepam) (NDC 00004-0068-01 (0.5mg), NDC 00004-0058-01 (1mg) and NDC 00004-0098-01 (2mg)). Based on our review, sole community hospitals (SCH), rural referral centers (RRC), critical access hospitals (CAH), and free standing cancer hospitals (CAN), may have made non-340B purchases of Klonopin that were eligible for 340B pricing, during the time period April 1, 2011 through December 31, 2021, and therefore may be owed a refund.

If any such entity believes that it may be owed a refund, please send an email to Genentech_340B_Refund_Ops@gene.com with "Attention: 340B Klonopin Refund" in the subject line at its earliest convenience with the best contact information (email and phone number), the entity name(s) and 340B ID(s), so that we may send a Refund Request Form and detailed information regarding the data we need to accurately calculate a refund, no later than September 30, 2024.

Genentech has asked the Office of Pharmacy Affairs ("OPA") to post this notice on OPA's public website to ensure transparency by providing access to information regarding Genentech's refund program to the public and specifically, to any affected 340B Covered Entity.